---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References"
description: "Reference list for the formulary evidence report on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis. 277 cited documents."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References

<a id="references"></a>

## 5 References

1. [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)
2. [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)
3. [Abuabara et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2966545/)
4. [Al Sawah et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28635342/)
5. [Alinaghi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29928910/)
6. [Alumis and Kaken press release, collaboration and licensing agreement (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/tm2510181d1_ex99-1.htm)
7. [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)
8. [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/)
9. [Alumis expanded access policy page](https://www.alumis.com/patients/expanded-access/)
10. [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)
11. [Alumis Form 10-Q, second quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm)
12. [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)
13. [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm)
14. [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)
15. [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)
16. [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)
17. [Alumis press release, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514xex99d1.htm)
18. [Alumis press release, first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm)
19. [Alumis press release, LUMUS topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-1.htm)
20. [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)
21. [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)
22. [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)
23. [Alumis press release, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)
24. [Alumis press release, third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_ex99-1.htm)
25. [Alumis press release, third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)
26. [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)
27. [Alumis press release, year end 2024 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)
28. [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)
29. [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)
30. [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)
31. [Amgen ENBREL prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103795s5605lbl.pdf)
32. [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)
33. [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)
34. [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)
35. [Armstrong and Read (2020b)](https://pubmed.ncbi.nlm.nih.gov/32427307/)
36. [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)
37. [Armstrong et al. (2013a)](https://pubmed.ncbi.nlm.nih.gov/23407990/)
38. [Armstrong et al. (2013b)](https://pubmed.ncbi.nlm.nih.gov/23360868/)
39. [Armstrong et al. (2013c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3647278/)
40. [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)
41. [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/)
42. [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)
43. [Armstrong et al. (2017c)](https://pubmed.ncbi.nlm.nih.gov/28303523/)
44. [Armstrong et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6025830/)
45. [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)
46. [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)
47. [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)
48. [Armstrong et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/35820547/)
49. [Armstrong et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37154473/)
50. [Armstrong et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10613163/)
51. [Armstrong et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11339701/)
52. [Armstrong et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12188513/)
53. [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)
54. [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)
55. [Armstrong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12873009/)
56. [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)
57. [Armstrong et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13578007/)
58. [Augustin et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456340/)
59. [Augustin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480266/)
60. [Basra et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17300244/)
61. [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf)
62. [Bellinato et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9184411/)
63. [Bissonnette et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6175198/)
64. [Bissonnette et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41191940/)
65. [Blauvelt et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391184/)
66. [Blauvelt et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/eadv_2024_pstr-pro_ole.pdf)
67. [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf)
68. [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)
69. [Blauvelt et al. (2025b)](https://data.mendeley.com/public-files/datasets/zs5xvkwpym/files/d4eed96a-ef9b-421e-91a5-551459647784/file_downloaded)
70. [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext)
71. [Blauvelt et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41260526/)
72. [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)
73. [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf)
74. [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/)
75. [Bożek and Reich (2017)](https://pubmed.ncbi.nlm.nih.gov/29068583/)
76. [Brezinski et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25565304/)
77. [Bristol Myers Squibb press release, BMS Patient Connect platform (2025)](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx)
78. [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)
79. [Budu-Aggrey et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6354959/)
80. [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)
81. [Burshtein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33253841/)
82. [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)
83. [California HCAI prescription drug WAC increases, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv)
84. [Carlisle et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7450401/)
85. [Carrico et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7688845/)
86. [Chat et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38331098/)
87. [Chen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40846809/)
88. [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)
89. [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)
90. [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634)
91. [ClinicalTrials.gov NCT05431634 version 1](https://clinicaltrials.gov/study/NCT05431634?tab=history&a=1)
92. [ClinicalTrials.gov NCT05600036](https://clinicaltrials.gov/study/NCT05600036)
93. [ClinicalTrials.gov NCT05600036 results](https://clinicaltrials.gov/study/NCT05600036?tab=results)
94. [ClinicalTrials.gov NCT05600036 version 1](https://clinicaltrials.gov/study/NCT05600036?tab=history&a=1)
95. [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)
96. [ClinicalTrials.gov NCT05739435 version 1](https://clinicaltrials.gov/study/NCT05739435?tab=history&a=1)
97. [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112)
98. [ClinicalTrials.gov NCT06586112 API record](https://clinicaltrials.gov/api/v2/studies/NCT06586112)
99. [ClinicalTrials.gov NCT06586112 version 1](https://clinicaltrials.gov/study/NCT06586112?tab=history&a=1)
100. [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738)
101. [ClinicalTrials.gov NCT06588738 version 1](https://clinicaltrials.gov/study/NCT06588738?tab=history&a=1)
102. [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)
103. [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)
104. [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)
105. [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774)
106. [ClinicalTrials.gov NCT06962774 version 1](https://clinicaltrials.gov/study/NCT06962774?tab=history&a=1)
107. [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579)
108. [CMS 2026 QCDR measure specifications (2026)](https://qpp-cm-prod-content.s3.amazonaws.com/uploads/3573/2026_QCDR_Measure_Specifications.xlsx)
109. [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)
110. [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)
111. [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)
112. [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)
113. [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)
114. [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)
115. [Dendrou et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5737835/)
116. [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)
117. [Dhana et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30590074/)
118. [Dowlatshahi et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24284419/)
119. [Eder et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26555117/)
120. [Eghlileb et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17459044/)
121. [Egilman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/)
122. [Ehst et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-treattotarget-fall-clinical.pdf)
123. [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)
124. [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)
125. [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)
126. [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)
127. [EMA psoriasis clinical investigation guideline (2004)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf)
128. [EU Clinical Trials Register 2022-002633-34](https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002633-34/CZ)
129. [FDA UNII record for envudeucitinib](https://precision.fda.gov/uniisearch/srs/unii/KD2MDJ4GAB)
130. [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/)
131. [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/)
132. [Feldman et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29357713/)
133. [Feldman et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398100/)
134. [Feldman et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398133/)
135. [Fredriksson and Pettersson (1978)](https://pubmed.ncbi.nlm.nih.gov/357213/)
136. [Fu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583370/)
137. [GBD 2019 IMID Collaborators (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10507198/)
138. [Gelfand et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17032986/)
139. [Gelfand et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18086997/)
140. [Gooderham et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41191932/)
141. [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)
142. [Grossschaedl et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11150751/)
143. [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)
144. [Guo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37956475/)
145. [Hagino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975169/)
146. [Hawkes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600287/)
147. [Hawkes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822976/)
148. [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)
149. [Hawro et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24852054/)
150. [Health Research Authority research summary, ESK-001 metformin and paroxetine study (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-study-on-impact-of-esk-001-pk-on-metformin-and-paroxetine-in-healthy-participants/)
151. [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/)
152. [Hendrix et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398188/)
153. [Hongbo et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16185263/)
154. [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)
155. [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf)
156. [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)
157. [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)
158. [Imafuku et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36882942/)
159. [Ishihara et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41657209/)
160. [Jalenques et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9558761/)
161. [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)
162. [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)
163. [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)
164. [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)
165. [Jaworecka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304988/)
166. [Jensen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10589750/)
167. [Jia et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32602762/)
168. [Karpoff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42913858/)
169. [Kim et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11966480/)
170. [Kong and Buzney (2026)](https://pubmed.ncbi.nlm.nih.gov/41739454/)
171. [Korman et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27061102/)
172. [Krueger et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34224773/)
173. [Kumar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13570483/)
174. [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)
175. [Kurd et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928071/)
176. [Langley et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24354461/)
177. [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/)
178. [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)
179. [Lebwohl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13650227/)
180. [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)
181. [Lønnberg et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23574549/)
182. [Lovell et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39395444/)
183. [Magnolo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13280295/)
184. [Marquez-Grap et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126447/)
185. [Martínez-García et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24836080/)
186. [McCoy et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37066447/)
187. [Mehrotra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40441292/)
188. [Mehta et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2894736/)
189. [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)
190. [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)
191. [Merola et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33934270/)
192. [Motedayen Aval et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12466084/)
193. [Mrowietz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436565/)
194. [Murage et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29718756/)
195. [Narayan et al. (2025)](https://www.alumis.com/file.cfm/18/docs/20250129_aad2025_pstr_biomarkers_final.pdf)
196. [Narayan et al. (2026a)](https://www.alumis.com/file.cfm/613/docs/20260427_sid2026_pstr_biomarkers_final.pdf)
197. [Narayan et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/eadv2026_biomarker-data-poster.pdf)
198. [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)
199. [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)
200. [National Psoriasis Foundation position statement on psoriasis severity (2025)](https://www.psoriasis.org/position-statement-on-psoriasis-severity/)
201. [National Psoriasis Foundation, FDA drops TB testing for Skyrizi (2026)](https://www.psoriasis.org/us-fda-drops-tb-testing-requirement/)
202. [National Psoriasis Foundation, TB testing for new oral treatment (2026)](https://www.psoriasis.org/tb-testing-new-oral-treatment/)
203. [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)
204. [Noot et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41161603/)
205. [Novartis COSENTYX prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s101;761349s016lbl.pdf)
206. [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf)
207. [Papp et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26089047/)
208. [Papp et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8163919/)
209. [Papp et al. (2024)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_2_for_website_aad_pres_vf.pdf)
210. [Papp et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354354/)
211. [Papp et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436474/)
212. [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)
213. [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)
214. [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)
215. [Park et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38914425/)
216. [Pasumarthi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42896634/)
217. [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41419127/)
218. [Paul et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26357944/)
219. [Pelet Del Toro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10238745/)
220. [Perlmutter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13423114/)
221. [Pilon et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30523738/)
222. [Piragine et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8953825/)
223. [Popatia et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31103568/)
224. [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)
225. [Reich et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33891380/)
226. [Rome et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12004245/)
227. [Ryan et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25824273/)
228. [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)
229. [Schaefer et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26253364/)
230. [Schneiderman and Derrick (2026)](https://pubmed.ncbi.nlm.nih.gov/42083649/)
231. [Semenov et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31415837/)
232. [Shah et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/36456639/)
233. [Shorla Oncology JYLAMVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212479s009lbl.pdf)
234. [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)
235. [Smith et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39079697/)
236. [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext)
237. [Snyder et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35618988/)
238. [Spuls et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20043014/)
239. [Stein Gold et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40976249/)
240. [Stein Gold et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42397072/)
241. [Stein Gold et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42954748/)
242. [Stiefel SORIATANE prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019821s029lbl.pdf)
243. [Strober et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500315/)
244. [Strober et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31425723/)
245. [Strober et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36115523/)
246. [Strober et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12619882/)
247. [Stuart et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8682265/)
248. [Sun Pharma ILUMYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761067s031lbl.pdf)
249. [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/)
250. [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/)
251. [Takeda press release, zasocitinib skin clearance across body sites (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase-3-psoriasis-skin-clearance/)
252. [Takeshita et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4549797/)
253. [Teeple and Fitzgerald (2022)](https://pubmed.ncbi.nlm.nih.gov/32479140/)
254. [Teeple and Muser (2019)](https://pubmed.ncbi.nlm.nih.gov/31199173/)
255. [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)
256. [Tilley et al. (2024)](https://www.alumis.com/file.cfm/18/docs/final_eadv_2024_biomarker_oral_presentation.pdf)
257. [Tilley et al. (2026)](https://www.alumis.com/file.cfm/613/docs/aad2026_biomarkers_final.pdf)
258. [Tsai et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11624152/)
259. [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)
260. [UCB CIMZIA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125160s315lbl.pdf)
261. [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)
262. [Ucpinar et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv2024_pstr_poppk-er_final.pdf)
263. [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)
264. [Vanderpuye-Orgle et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25882886/)
265. [Vazquez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372843/)
266. [Villacorta et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7497177/)
267. [Wan et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963348/)
268. [World Health Organization INN stem book (2024)](https://iris.who.int/server/api/core/bitstreams/a042b526-4e17-4f77-b437-42ce85e66219/content)
269. [World Health Organization proposed INN list 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)
270. [Wu et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29658383/)
271. [Wu et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32233828/)
272. [Wu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9823180/)
273. [Xu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10272578/)
274. [Yang et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32716651/)
275. [Zhao et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30470802/)
276. [Zheng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38899421/)
277. [Zhou et al. (2025)](https://www.alumis.com/file.cfm/613/docs/isds_poster_final.pdf)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
